• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Provides First Look at Recently Completed Hydration Expansion at DCAT Week 2025

    3/17/25 7:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies

    RADNOR, Pa., March 17, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services in the life sciences and advanced technology industries, announces that Ger Brophy, PhD, head of Avantor's Scientific Advisory Board, will present highlights of the recently completed expansion at its flagship European manufacturing site at Drug, Chemical & Associated Technologies Association (DCAT) Week 2025. Dr. Brophy's presentation will take place as part of the Member Company Announcement Forum on Monday, March 17, at approximately 9:15 am eastern. DCAT Week, which runs March 17 – 20 in New York City, is the premier annual event for companies engaged in the Global Bio/Pharmaceutical Manufacturing Value Chain. 

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    The new production facility's advanced technologies quadruple the site's capacity for manufacturing, formulating, and filling United States Pharmacopoeia (USP) purified water and Water for Injection (WFI)-based hydration solutions. These high-purity solutions are essential in buffer preparations, cell culture media, clean-in-process (CIP), and formulation processes, supporting the stability, efficacy, and safety of biologics and other life-saving therapies.

    "This latest investment strengthens our global manufacturing network, building important capacity and bringing our operations closer to customers," said Benoit Gourdier, EVP of Avantor's Bioscience Production Segment. "It ensures a dependable supply of high-quality products while strengthening our role as a trusted partner, working alongside biopharma manufacturers to produce life changing therapies." 

    In recent years, Avantor has made substantial investments to enhance global production capacity and introduce new products to serve the growing bioprocessing needs of drug manufacturers. This project in Poland builds on a recent expansion at the Aurora, Ohio manufacturing site, which added significant hydrated solutions capacity to support the North American market. Additionally, a new production facility at the Phillipsburg, N.J. manufacturing site has doubled the output of synthesized salts, a vital ingredient in hydration manufacturing. These investments improve Avantor's global production efficiency, optimize supply chain operations and strengthen the availability of raw materials for biopharma applications to customers worldwide. 

    In addition to increasing manufacturing capacity, Avantor has also expanded its research and innovation capabilities. In November 2024, the company opened its new 60,000-square-foot Bridgewater Innovation Center in New Jersey doubling its previous lab and pilot plant capacity, enhancing collaboration and bioprocessing innovation. Designed for upstream and downstream development, analytical testing, and viral vector research, the state-of-the-art facility accelerates scale-up and customization across the entire bioprocessing workflow. 

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development, and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter), and Facebook.

    Global Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected]

    Investor Relations Contact

    Allison Hosak

    Senior Vice President, Global Communications

    Avantor

    908-329-7281

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-provides-first-look-at-recently-completed-hydration-expansion-at-dcat-week-2025-302402531.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings